MX2016014761A - Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2). - Google Patents

Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).

Info

Publication number
MX2016014761A
MX2016014761A MX2016014761A MX2016014761A MX2016014761A MX 2016014761 A MX2016014761 A MX 2016014761A MX 2016014761 A MX2016014761 A MX 2016014761A MX 2016014761 A MX2016014761 A MX 2016014761A MX 2016014761 A MX2016014761 A MX 2016014761A
Authority
MX
Mexico
Prior art keywords
detecting
assay
cell populations
disorder
disease
Prior art date
Application number
MX2016014761A
Other languages
English (en)
Inventor
A Welcher Andrew
J Boedigheimer Michael
Gorski Kevin
R Parnes Jane
BIGLER Jeanette
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2016014761A publication Critical patent/MX2016014761A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4715—Cytokine-induced proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5409—IL-5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción se refiere a un método para detectar subpoblaciones de linfocitos T colaboradores o CTL en un sujeto afectado por una enfermedad o un trastorno con un componente inmunitario. Los métodos también son útiles para determinar la eficacia de un tratamiento de la enfermedad o trastorno detectando la desviación de los linfocitos T colaboradores y CTL en una dirección terapéutica o adversa.
MX2016014761A 2014-05-16 2015-05-15 Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2). MX2016014761A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461994430P 2014-05-16 2014-05-16
PCT/US2015/030940 WO2015175861A1 (en) 2014-05-16 2015-05-15 Assay for detecting th1 and th2 cell populations

Publications (1)

Publication Number Publication Date
MX2016014761A true MX2016014761A (es) 2017-05-25

Family

ID=53284553

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014761A MX2016014761A (es) 2014-05-16 2015-05-15 Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).

Country Status (7)

Country Link
US (2) US10156562B2 (es)
EP (2) EP3467501B1 (es)
JP (1) JP6671298B2 (es)
AU (1) AU2015259053B2 (es)
CA (1) CA2949237C (es)
MX (1) MX2016014761A (es)
WO (1) WO2015175861A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7173867B2 (ja) * 2016-04-22 2022-11-16 ベクトン・ディキンソン・アンド・カンパニー 多重高分子色素デバイス及びその使用方法
WO2017222998A1 (en) * 2016-06-20 2017-12-28 Beckman Coulter, Inc. Dry-down processes for dye-conjugated reagents
US11992844B2 (en) 2018-11-13 2024-05-28 Becton, Dickinson And Company Dried reagent strainers and methods for making and using the same
EP4009953A4 (en) * 2019-08-07 2023-08-23 Icahn School of Medicine at Mount Sinai METHOD OF TREATMENT OF KELOIDS

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5714465A (en) 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
CA2087086A1 (en) 1992-01-22 1993-07-23 Leon Wmm Terstappen Multidimensional cell differential analysis
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US7045128B2 (en) 1993-05-24 2006-05-16 Immunex Corporation Antibodies against flt3-ligand
US6630143B1 (en) 1993-05-24 2003-10-07 Immunex Corporation Antibodies against flt3 ligand
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
EP0879056B1 (en) 1996-01-23 2002-05-02 ICN Pharmaceuticals, Inc. Modulation of th1/th2 cytokine expression by ribavirin in activated t-lymphocytes
EP0938499A1 (en) 1996-07-19 1999-09-01 Amgen Inc. Analogs of cationic proteins
KR100518903B1 (ko) 1996-10-25 2005-10-06 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 Ｔｈ2 매개 질병 및 관련 질병의 치료용 면역 반응 조절 화합물
US7514232B2 (en) 1996-12-06 2009-04-07 Becton, Dickinson And Company Method for detecting T cell response to specific antigens in whole blood
AU713473B2 (en) 1996-12-23 1999-12-02 Immunex Corporation Receptor activator of NF-kappa B, receptor is member of TNF receptor superfamily
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
RO128635A2 (ro) 1997-04-16 2013-07-30 Amgen Inc. Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ATE305510T1 (de) 1997-12-17 2005-10-15 Immunex Corp Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden
AU755391B2 (en) 1997-12-23 2002-12-12 Immunex Corporation SIGIRR DNA and polypeptides
AU1682699A (en) 1997-12-25 1999-07-19 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
WO1999037773A1 (en) 1998-01-23 1999-07-29 Immunex Corporation Acpl dna and polypeptides
DE69939982D1 (de) 1998-08-07 2009-01-08 Immunex Corp B7l-1 moleküle
AU776825B2 (en) 1998-08-07 2004-09-23 Immunex Corporation Molecules designated LDCAM
AU1230600A (en) 1998-10-28 2000-05-15 President And Fellows Of Harvard College Regulation of th2 cell activity by modulation of nfatp and nfat4 activity
DE69936105T3 (de) 1998-11-13 2017-07-27 Immunex Corporation Menschliche tslp nukleinsäuren und polypeptide
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
ES2327102T3 (es) 2000-09-05 2009-10-26 Amgen Inc. Moleculas analogas al receptor de tnf y usos de las mismas.
WO2002053596A2 (en) 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
WO2002089832A2 (en) 2001-05-09 2002-11-14 Alk-Abelló A/S Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
US7012689B2 (en) 2001-05-17 2006-03-14 Dako Colorado, Inc. Flow cytometer with active automated optical alignment system
AU2002356511A1 (en) 2001-07-30 2003-04-01 Immunex Corporation T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
EP3184539A3 (en) 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Psma antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2467597A1 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
EP1461082A4 (en) 2001-12-03 2006-06-28 Abgenix Inc ANTIBODIES AGAINST THE TUMOR ANTIGEN OF CARBON IX ANHYDRASE (CA IX)
EP1467757B1 (en) 2001-12-28 2008-05-07 Amgen Fremont Inc. Use of antibodies against the muc18 antigen
ATE364618T1 (de) 2001-12-28 2007-07-15 Amgen Fremont Inc Antikörper gegen das muc18-antigen
JP2005516965A (ja) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗ｍｕｃ１８抗体を使用する方法
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
ATE435239T1 (de) 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
EP1494714A4 (en) 2002-04-05 2008-03-05 Amgen Inc HUMAN ANTI-OPGL NEUTRALIZING ANTIBODIES AS SELECTIVE OPGL PATH HEMMER
JP2004041121A (ja) 2002-07-12 2004-02-12 Hitachi Ltd アレルギー解析方法及びシステム
UA87979C2 (ru) 2002-08-19 2009-09-10 Астразенека Аб Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1)
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
EA018072B1 (ru) 2002-09-06 2013-05-30 Амджен Инк. Антитело к рецептору интерлейкина-1 типа 1 (il-1r1) и его применение
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
RU2377253C2 (ru) 2002-12-02 2009-12-27 Амген Фремонт,Инк. Антитела, специфичные к фактору некроза опухолей, и их применение
KR20130065723A (ko) 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
SI1648509T1 (sl) 2003-07-15 2012-12-31 Amgen Inc. Humana protitelesa, ki nevtralizirajo anti-ngf, kot selektivni inhibitorji poti nfg
JP2007500132A (ja) 2003-07-25 2007-01-11 アムジェン インコーポレイテッド Ｌｄｃａｍのアンタゴニストおよびアゴニスト、並びにその使用法
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
ATE548388T1 (de) 2003-11-07 2012-03-15 Immunex Corp An den interleukin-4-rezeptor bindende antikörper
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
DK2177537T3 (da) 2004-01-09 2011-12-12 Pfizer Antistoffer til MAdCAM
US20050287140A1 (en) 2004-04-23 2005-12-29 Amgen Inc. Antibodies to angiogenesis inhibiting domains of CD148
WO2005117970A2 (en) 2004-04-23 2005-12-15 Amgen, Inc. Antibodies of angiogenesis inhibiting domains of cd148
KR20070085199A (ko) 2004-06-04 2007-08-27 디자이너 몰레큘스 인코퍼레이티드 자유-라디칼에 경화되는 폴리에스테르 및 그 사용 방법
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
DE602005025525D1 (de) 2004-11-17 2011-02-03 Amgen Inc Vollständige humane monoklonale antikörper gegen il-13
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
CA2590164A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
WO2006104677A2 (en) 2005-03-24 2006-10-05 Millennium Pharmaceuticals, Inc. Antibodies that bind ov064 and methods of use therefor
US7807159B2 (en) 2005-04-25 2010-10-05 Amgen Fremont Inc. Antibodies to myostatin
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
NO345593B1 (no) 2005-07-18 2021-05-03 Amgen Inc Humane anti-B7RP1 nøytraliserende antistoffer
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
PT2447283E (pt) 2005-09-07 2015-10-08 Pfizer Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1)
RS52357B (en) 2005-12-13 2012-12-31 Medimmune Limited BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
EP2035454A2 (en) 2006-05-19 2009-03-18 Amgen, Inc. Antibodies to sars coronavirus
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8232372B2 (en) 2006-12-14 2012-07-31 Schering Corp. Engineered anti-TSLP antibody
US8101426B2 (en) 2007-03-02 2012-01-24 Icyt Mission Technology, Inc. System and method for the measurement of multiple fluorescence emissions in a flow cytometry system
UY30994A1 (es) 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
CN102027012A (zh) 2007-06-20 2011-04-20 Irm责任有限公司 用于治疗变应性疾病的方法和组合物
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
EA201000131A1 (ru) * 2007-08-02 2010-08-30 АйЭсЭс ИММЬЮН СИСТЕМ СТИМУЛЕЙШН АБ Диагностика, определение стадии и мониторинг воспалительного заболевания кишечника
RS56743B1 (sr) 2007-08-21 2018-03-30 Amgen Inc Humani c-fms antigen vezujući proteini
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
MX2010011717A (es) 2008-05-01 2010-11-30 Amgen Inc Anticuerpos anti-hepcidina y metodos de uso.
US7932503B2 (en) 2008-05-16 2011-04-26 David R. Parks Method for pre-identification of spectral overlaps within fluorescent dye and detector combinations used in flow cytometry
AU2009322105B2 (en) * 2008-12-04 2015-07-02 Massachusetts Institute Of Technology Method for diagnosing allergic reactions
MX2011009897A (es) 2009-03-20 2011-12-08 Amgen Inc Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
PT3295957T (pt) 2010-01-15 2019-11-12 Kirin Amgen Inc Formulação de anticorpo anti il-17ra e regimes terapêuticos para o tratamento de psoríase
WO2012148549A1 (en) * 2011-02-25 2012-11-01 Benaroya Research Institute Detection of an immune response
AU2012328952A1 (en) * 2011-10-28 2014-05-01 Merck Sharp & Dohme Corp. IL-19 as a biomarker of TSLP treatment
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers

Also Published As

Publication number Publication date
EP3143404A1 (en) 2017-03-22
EP3467501A1 (en) 2019-04-10
CA2949237A1 (en) 2015-11-19
US10156562B2 (en) 2018-12-18
US20190219563A1 (en) 2019-07-18
EP3143404B1 (en) 2018-08-29
JP2017518494A (ja) 2017-07-06
WO2015175861A1 (en) 2015-11-19
JP6671298B2 (ja) 2020-03-25
EP3467501B1 (en) 2020-11-04
US11156600B2 (en) 2021-10-26
US20170082608A1 (en) 2017-03-23
AU2015259053A1 (en) 2016-11-24
CA2949237C (en) 2022-08-23
AU2015259053B2 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
IL280743B (en) Methods for enriching and producing immune cell populations for stress treatment
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
EP3240911A4 (en) Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
PH12017500153B1 (en) Compositions and methods of use for treating metabolic disorders
IL246645A0 (en) Cells for immunotherapy engineered to target an antigen present on immune cells and pathological cells
EP3129473B8 (en) Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
EP3131931A4 (en) Methods for increasing red blood cell levels and treating sickle-cell disease
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
EP3186397C0 (en) USE OF BIOMARKERS OF CIRCULATING CELLS IN THE BLOOD FOR THE DETECTION AND DIAGNOSIS OF DISEASES, AND THEIR ISOLATION PROCESSES
IL250639B (en) A method for improving the function of an immune cell and a method for evaluating multiple functions of an immune cell
IL251977A0 (en) Tests for detecting T-cell immune subsets and methods for using them
MY173953A (en) Recombinant host cells for the production of malonate
EA201692254A1 (ru) Иммуномодулирующие прогениторные (имп) клетки
EP3209998A4 (en) Method and system for detection of disease agents in blood
MX365403B (es) Peptidos y metodos para usarlos.
MX2016014761A (es) Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
EP3129034A4 (en) Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
MX362497B (es) Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
TWD180080S (zh) 電池壓緊裝置之部分
GB201403115D0 (en) Red blood cell detection
DK3144002T3 (da) Kontrolmiddel til gm-csf-producerende t-celler og th1/th2-immunbalanceregulator
ES1074026Y (es) Dispositivo estimulador del aparato genital masculino y femenino.
EA201890489A1 (ru) Car макрофагов (moto-car) в иммунотерапии
MY168100A (en) Failure diagnosis device and failure diagnosis method
UA98639U (ru) Способ коррекции иммунного статуса у больных генерализованным тревожным расстройством

Legal Events

Date Code Title Description
FG Grant or registration